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ABSTRACT
Breast cancer patients who initially respond to cancer therapies often succumb 
to distant recurrence of the disease. It is not clear why people with the same type 
of breast cancer respond to treatments differently; some escape from dormancy and 
relapse earlier than others. In addition, some tumor clones respond to immunotherapy 
while others do not. We investigated how autophagy plays a role in accelerating 
or delaying recurrence of neu-overexpressing mouse mammary carcinoma (MMC) 
following adriamycin (ADR) treatment, and in affecting response to immunotherapy. 
We explored two strategies: 1) transient blockade of autophagy with chloroquine (CQ), 
which blocks fusion of autophagosomes and lysosomes during ADR treatment, and 2) 
permanent inhibition of autophagy by a stable knockdown of ATG5 (ATG5KD), which 
inhibits the formation of autophagosomes in MMC during and after ADR treatment. 
We found that while CQ prolonged tumor dormancy, but that stable knockdown of 
autophagy resulted in early escape from dormancy and recurrence. Interestingly, 
ATG5KD MMC contained an increased frequency of ADR-induced polyploid-like cells and 
rendered MMC resistant to immunotherapy. On the other hand, a transient blockade of 
autophagy did not affect the sensitivity of MMC to immunotherapy. Our observations 
suggest that while chemotherapy-induced autophagy may facilitate tumor relapse, 
cell-intrinsic autophagy delays tumor relapse, in part, by inhibiting the formation of 
polyploid-like tumor dormancy. 
INTRODUCTION
Autophagy plays a paradoxical role in the 
promotion and inhibition of cancer. On the one hand, 
autophagy has a cancer-promoting role by protecting 
tumor cells from chemotherapy or providing a source 
of energy for tumor cells to survive under hypoxic and 
acidic conditions despite the lack of mature vessels  [1]. 
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On the other hand, inhibition of autophagy by disruption 
of Beclin 1 or deletion of ATG5 increases the frequency 
of spontaneous malignancies  [2] or liver tumor  [3], 
respectively. Recently, four different mechanisms have 
been proposed to describe paradoxical functions of 
autophagy in cancer, which include cytotoxic, cytostatic, 
cytoprotective and non-protective autophagy  [4]. There 
are also three major types of autophagy which include 
micro-autophagy involving the direct engulfment of 
cytosolic material by lysosomes through invagination, 
chaperone-mediated autophagy involving HSP70 and the 
lysosomal membrane associated protein 2 A (LAMP2A), 
and macro-autophagy which is a highly conserved 
pathway involving the formation of autophagosomes, 
which fuse with lysosomes. To this end, ATG5 is 
involved in the elongation of autophagosomes to engulf 
toxic material for degradation. A stable knockdown 
of ATG5 results in the inhibition of the formation of 
autophagosomes and progression of macro-autophagy 
[5]. Chloroquine (CQ), on the other hand, does not have 
any effects on autophagosomes but it blocks the fusion of 
autophagosomes and lysosomes, thereby preventing the 
completion of macro-autophagy. In order to investigate 
the role of macro-autophagy in tumor dormancy and 
relapse, we performed a transient inhibition of macro-
autophagy by means of CQ during chemotherapy, 
which mainly inhibits chemotherapy-induced autophagy 
while cell-intrinsic autophagy will be restored after 
the completion of chemotherapy. We also performed a 
permanent inhibition of cell-intrinsic macro-autophagy 
by a stable knockdown of ATG5 in tumor cells. We 
demonstrated that cell-intrinsic, but not chemotherapy-
induced, autophagy can inhibit tumor relapse.
RESULTS
Adriamycin induces autophagy in MMC
In order to determine whether ADR induces 
autophagy and in turn establishes tumor dormancy, MMC 
cells were treated with ADR in the presence or absence of 
CQ, a pharmacological agent used to block the final stages 
of autophagy, specifically the fusion of autophagosomes 
with lysosomes that is necessary for digestion of the cargo 
in the autophagosomes (frequently termed “autophagic 
flux”). CQ blocked this autophagic flux as evidenced by 
the enhanced accumulation of acidic vesicles (red signals) 
(Figure 1A, ADR and ADR+CQ). We further monitored 
degradation of the p62/SQSTM1 protein as a marker of 
autophagic flux, and LC.3B expression as a marker of 
autophagosomes formation (since LC3 is a component 
of the autophagosomes). As shown in Figure 1B, ADR 
did not induce degradation of p62/SQSTM1 although it 
elevated LC.3B, suggesting that ADR induces autophagy 
but fails to drive autophagy to completion and p62/
SQSTM1 degradation.  
A transient blockade of autophagy by CQ during 
ADR treatment delays tumor relapse in vitro but 
not in vivo
Since CQ is being used to sensitize tumor cells 
susceptible to chemotherapy  [6], we sought to determine 
whether blockade of autophagy by CQ during ADR 
treatment affects tumor dormancy and relapse. We showed 
that the presence of CQ during ADR treatment, in vitro, 
resulted in prolonging tumor dormancy such that, while 
ADR treated MMC resumed cell proliferation 6 weeks after 
the treatment, ADR+CQ treated MMC remained dormant 
(Figure 2A). In order to confirm tumor cell relapse after 6 
weeks, flow cytometry analysis of ADR-treated MMC was 
performed, and indicated a shift of Ki67- non-proliferating 
cells to Ki67+ proliferating cells with a greater viability 
(Figure 2B). In fact, MMC cells remained apoptotic by 
producing floater dead cells following ADR treatment 
(Supplementary Figure 1A) which compensated for cell 
proliferation and maintained tumor dormancy for 3 weeks 
after the completion of ADR treatment. Follow up studies on 
floater cells showed they were all apoptotic (Supplementary 
Figure 1B). A transient blockade of autophagy by CQ did 
not affect susceptibility of tumor cells to ADR-induced 
apoptosis (Supplementary Figure 2). On the other hand, a 
transient blockade of autophagy during ADR chemotherapy, 
in vivo, did not prolong tumor dormancy in FVBN202 mice 
(Supplementary Figure 3).
A transient blockade of autophagy by CQ during 
ADR treatment does not change susceptibility of 
tumor cell to immunotherapy
In order to determine whether a transient blockade 
of autophagy during ADR treatment affects susceptibility 
of dormant MMC to immunotherapy, dormant MMC were 
cultured with either IFN-γ or MMC-reactive T cells three 
weeks after treatment with ADR or ADR+CQ. As shown 
in Figure 3, untreated MMC or dormant MMC treated 
with ADR or ADR+CQ all remained susceptible to IFN-γ 
treatment or T cells. 
A stable knockdown of autophagy reduces 
susceptibility of MMC to ADR treatment 
CQ only transiently blocks fusion of autophagosomes 
and lysosomes during ADR treatment such that after 
removal of CQ, accumulated autophagosomes could 
eventually be fused with lysosomes to complete 
autophagy. In order to determine the role of autophagy in 
tumor dormancy or relapse, we used shRNA for a stable 
knockdown of ATG5 (ATG5KD) which inhibits formation 
of autophagosomes in MMC. Scrambled shRNA was used 
as control (Supplementary Figure 4A). The ATG5KD MMC 
and scrambled control MMC were irradiated to confirm that 
ATG5KD MMC cells were deficient in autophagy, using p62 
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and LC.3B as read outs (Supplementary Figure 4B). Tumor 
cells remained intact for the expression of neu antigen, 
as well as cell proliferation in vitro and in vivo following 
knockdown of autophagy (Supplementary Figure 4C–4E). 
Flow cytometry analysis determined a lower level of 
viability in MMC compared with ATG5KD MMC following 
ADR treatment (Figure 4). 
A stable knockdown of autophagy results in 
earlier tumor relapse associated with increased 
frequency of polyploid-like cells and resistance to 
immunotherapy
In order to determine whether a higher viability 
of ATG5KD MMC following ADR treatment (Figure 4) 
facilitates an earlier tumor relapse compared with wild 
type MMC, follow up studies were performed for three 
weeks after ADR treatment. As shown in Figure 5A, 
ATG5KD MMC survived better than autophagy-competent 
MMC following ADR treatment showing a significantly 
higher number of cells by 3 weeks after the treatment. 
Flow cytometry analysis of tumor cells showed greater 
levels of apoptosis in wild type MMC compared with 
ATG5KD MMC (Figure 5B, p < 0.001). Interestingly, 
ATG5KD MMC cells contained a higher number of 
polyploid-like cells following ADR treatment compared 
with autophagy-competent MMC (Figure 5B, p < 0.03). 
In order to determine the in vivo relevance of our 
in vitro findings, FVBN202 mice were used. Tumor 
dormancy was first established by ADR treatment in vitro; 
FVBN202 mice (n = 7/group) were then challenged i.v. 
with one million viable dormant tumor cells. Animals 
were then sacrificed when they became moribund (lost 
10% weight) as a result of massive lung metastasis. As 
can be seen in Figure 6A, animals that were challenged 
with ADR-treated ATG5KD MMC developed lung 
metastasis significantly sooner than those that were 
challenged with ADR-treated MMC. Hematoxylin/eosin 
and immunohistochemistry analyses of tumor lesions 
determined a higher frequency of polyploid-like and Ki67+ 
tumor cells in animals that were challenged with ADR-
treated ATG5KD MMC (Figure 6B). Finally, ATG5KD MMC 
were found to be resistant to T cell-induced apoptosis 
compared with autophagy-competent MMC (Figure 7).
DISCUSSION
Cell-intrinsic autophagy is an ongoing process, which 
regulates cellular metabolism and homeostasis. Autophagy 
is also induced by insults such as chemotherapy. Here, we 
studied a paradoxical role of autophagy in tumor promotion 
and tumor inhibition by a transient inhibition of autophagy 
only during chemotherapy or a stable knockdown of 
autophagy in MMC tumor cells. While the former 
transiently blocked autophagy and cell-intrinsic autophagy 
was restored after the completion of chemotherapy, 
the latter permanently blocked chemotherapy-induced 
autophagy and cell-intrinsic autophagy. We demonstrated 
that inhibition of chemotherapy-induced autophagy 
by CQ did not increase susceptibility of tumor cells 
to chemotherapy-induced apoptosis. Nevertheless, 
chemotherapy-induced autophagy appeared to accelerate 
tumor relapse such that use of CQ during chemotherapy 
delayed tumor relapse in vitro. Our observation is 
consistent with other reports showing that increased 
autophagy in residual breast cancer after neoadjuvant 
chemotherapy was correlated with increased risk of tumor 
relapse  [7]. A transient blockade of autophagy during 
chemotherapy of tumor-bearing animals did not affect 
tumor relapse, perhaps, because tumor inhibitory effects of 
in vivo chemotherapy was not as effective as in vitro drug 
treatment. Also, chemotherapy-induced autophagy did not 
affect the sensitivity of tumor cells to apoptosis induced by 
IFN-γ or tumor-reactive T cells. 
Figure 1: CQ blocks ADR-induced autophagy. MMC tumor cells received three daily doses of ADR alone (1 µM ADR for 2 hrs) 
(ADR) or in the presence of CQ (10 µM 3 hrs before ADR and 2 hrs during ADR treatment) (ADR+CQ), washed after each daily treatment 
and analyzed by acridine orange (AO) one day after the last treatment. Untreated MMC (Medium) or MMC treated with CQ (CQ) served 
as controls. (A) Acridine orange (AO) staining was analyzed for acidic vesicles (red) using image cytometry. Data represent triplicate 
experiments. (B) Levels of p62/SQSTM1 and LC.3B after treatment with ADR ± CQ indicative of autophagy induction in the absence of 
autophagic flux (B). 
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We also demonstrated that, unlike chemotherapy-
induced autophagy, cell-intrinsic autophagy accelerated 
tumor relapse. A stable knockdown of cell-intrinsic 
autophagy by ATG5 shRNA resulted in a reduced 
sensitivity of tumor cells to chemotherapy- or T cell-
induced apoptosis, and accelerated tumor relapse 
in vivo. These effects coincided with an increased 
frequency of multinuclear polyploid-like dormant cells. 
These observations suggest that chemotherapy-induced 
autophagy could have tumor-promoting effects and 
facilitate tumor relapse, whereas cell-intrinsic autophagy 
could synergize with cancer therapeutics and delay tumor 
relapse. In fact, cell-intrinsic autophagy would seem 
to inhibit the formation of multinuclear cells following 
chemotherapy, and to prevent chemotherapy-induced 
genetic instability associated with resistance to cancer 
therapeutics. Similar observations have been made in 
other breast tumor models by showing that CQ but not 
knockdown of Beclin 1 or ATG12 sensitized the tumor 
to chemotherapy  [8]. Therefore, anti-tumor effects of 
autophagy inhibitors such as CQ is likely to be because 
of the inhibition of chemotherapy-induced autophagy 
while anti-tumor effects of autophagy inducers such 
as rapamycin may result from enhanced cell-intrinsic 
autophagy  [9, 10]. It has been reported cancer stem cells 
play a role in tumor dormancy  [11] and drug resistance 
[12], and that immunotherapeutic targeting of breast 
cancer stem cells inhibits growth of mammary carcinoma 
[13]. However, we did not detect the enrichment of 
CD44+CD24- cancer stem cells following ADR-induced 
tumor dormancy (data not shown). 
Anticancer drugs and ionizing radiation tend 
to induce autophagy in tumor cells  [14]. Treatment-
induced autophagy could lead to apoptosis  [15] and 
tumor cell dormancy  [16]. We have already reported that 
dormant tumor cells established by ADR treatment or 
radiation therapy, in vitro, developed resistance to these 
treatments but remained susceptible to immunotherapy 
[17]. Therefore, evaluation of apoptosis or tumor 
growth inhibition as a single factor without evaluating 
Figure 2: ADR-induced dormant tumor cells remain dormant in the presence of CQ. MMC tumor cells were treated with 3 
daily doses of ADR (1 uM for 2 hrs), with one group receiving CQ (10 uM) 3 hrs prior to and during ADR treatment. Both groups remained 
untreated for 3 weeks and 6 weeks, in vitro. (A) Adherent viable cells were counted using trypan blue exclusion at various time points. 
Data represent 3 replicates ± SEM. (B) At weeks 3 and 6 post-treatment, Ki-67 expression (upper panel) and viability (lower panel) were 
quantified within the population of adherent tumor cells. Data represent 2–3 replicates ± SEM. Four independent experiments have been 
carried out which have shown similar results.
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Figure 3: Dormant tumor cells established by ADR or ADR+CQ remain susceptible to immunotherapy. The in vitro 
tumor dormancy was established three weeks after three daily treatments of MMC with ADR or ADR+CQ. Untreated MMC cells were used 
as control. (A) Apoptosis was determined by FVS viability staining in MMC (control), ADR-treated dormant MMC (ADR), ADR+CQ-
treated dormant MMC (ADR+CQ), as well as control MMC cultured with three daily doses of IFN-g and analyzed two days later (50 
ng/ml) (IFN-g), ADR-treated dormant MMC cultured with three daily doses of IFN-g (50 ng/ml) and analyzed two days later (ADR > 
IFN-g), or ADR+CQ-treated dormant MMC cultured with three daily doses of IFN-g (50 ng/ml) and analyzed two days later (ADR+CQ 
> IFN-g). (B) Apoptosis was determined by FVS viability staining of MMC (control), MMC cultured with MMC-sensitized T cells for 48 
hrs (T cells), ADR-treated dormant MMC (ADR), ADR-treated dormant MMC cultured with MMC-sensitized T cells for 48 hrs (ADR > T 
cells), ADR+CQ-treated dormant MMC (ADR+CQ), or ADR+CQ-treated dormant MMC cultured with MMC-sensitized T cells for 48 hrs 
(ADR+CQ > T cells). Splenic T cells were collected from MMC tumor-bearing FVBN202 mice.
Figure 4: Autophagy knockdown tumor cells become less susceptible to ADR-induced apoptosis. Autophagy-deficient 
MMC (ATG5KD MMC) or autophagy-competent MMC (MMC) were treated with a single dose of ADR alone (1 uM ADR for 2 hrs). 
Tumor cells were analyzed by Annexin V/PI staining prior to treatment (Day 0) or three days after the treatment (Day 4). Experiments were 
performed in triplicates.  
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tumor dormancy and relapse may not be sufficient 
for understanding anti-cancer efficacy of autophagy 
inhibitors such as CQ. Inhibition of autophagy by CQ 
during chemotherapy diminishes the expression of DNA 
repair proteins, resulting in tumor growth inhibition in 
carboplatin-resistant BRCA1 wild-type TNBC orthotopic 
xenografts  [18]. In triple negative breast cancer, CQ 
sensitizes tumor cells to paclitaxel chemotherapy  [19]. 
In several tumor models, CQ synergistically augmented 
sunitinib cytotoxicity on tumor cells  [6]. However, the 
role of CQ in inhibiting tumor recurrence has yet to be 
determined.
Cells that are deficient in autophagy show increased 
levels of reactive oxygen species which result in the 
accumulation of DNA damage, increased double-strand 
breaks and polyploid nuclei  [20, 21].  To this end, 
cell-intrinsic autophagy protects the cell from genomic 
instability induced by the accumulation of toxins within 
the cell  [22]. It has been reported that Beclin1 knockout 
mice fail to maintain genomic integrity by increasing DNA 
double stranded breaks and gene amplifications  [20]. A 
higher expression of Beclin 1 in healthy breast tissue than 
in breast cancer suggests a deficiency in cell-intrinsic 
autophagy in tumors  [23], which could contribute to 
genomic instability during tumorigenesis. In breast cancer 
patients who received adjuvant chemotherapy, presence of 
tumor cell intrinsic autophagy contributed to reduced risk 
of tumor relapse  [24]. Expression of ATG5 in the tumor 
specimens is also associated with relapse-free survival 
in breast cancer patients  [25]. In glioma, reduced tumor 
cell progression and relapse by knockdown of CDGSH 
iron sulfur domain 2 (CISD2) was associated with the 
activation of Beclin 1-mediated autophagy  [26]. 
Our observations suggest that any deficiency 
in tumor cell-intrinsic autophagy could result in a 
reduced sensitivity of breast cancer to chemotherapy or 
immunotherapy. Therefore, IHC analysis of tumor biopsies 
before and after neoadjuvant or adjuvant chemotherapy 
could determine cell-intrinsic and chemotherapy-induced 
autophagy, respectively, and in turn might predict the risk 
of distant recurrence of the diseases accordingly. In future 
studies, other murine and human breast tumor cell lines 
as well as other types of carcinoma cells should be used 
in order to determine whether our findings offer a general 
mechanism of autophagy-associated tumor dormancy and 
relapse, or it might be a cancer specific phenomenon. 
MATERIALS AND METHODS
Tumor cell line
The neu overexpressing mouse mammary carcinoma 
(MMC) cell line was established from spontaneous 
mammary tumors harvested from FVBN202 mice  [27]. 
Tumor cells were maintained in RPMI 1640 supplemented 
with 10% FBS. 
Genetic silencing of ATG5 in MMC
Mission shRNA bacterial stocks for ATG5 and 
scrambled Control were purchased from Sigma Aldrich. 
Lentiviruses were produced in HEK 293TN cells co-
transfected using Endo F ectinTM Lenti Transfection 
Reagent (GeneCopoeia, 1001–01) with a packaging 
mixture of psPAX2 and pMD2.G constructs (Addgene). 
Media containing the viruses was used to infect MMC 
cells; puromycin (1 μg/ml) was used as a selection marker 
to enrich for infected cells. 
Antibodies
All antibodies were purchase from Biolegend 
(San Diego, CA) unless otherwise stated. Antibodies 
were used as instructed by the supplier. Antibodies 
Figure 5: ADR-induced tumor dormancy in autophagy knockdown tumor cells with polyploid-like morphology 
compared with autophagy competent tumor cells, in vitro. MMC or ATG5KD MMC tumor cells (3 million cells, Day 0) were 
treated with 3 daily doses of ADR (1uM for 2 hrs), and viable cells were counted at week 3 using trypan blue exclusion. Data represent 
triplicate experiments (A). Dot plots from each experimental group gated for cell cycle phase based upon DNA content (7-AAD) and Ki-67 
expression. Events falling to the left of the G1/G0 gates are considered apoptotic cells (AP). Events falling to the far right of the G2/M gate 
are considered polyploid-like cells (Poly) (B). Three independent experiments have been performed and data represent 3 replicates ± SEM.
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Figure 6: Earlier relapse of autophagy knockdown tumor cells with polyploid morphology compared with autophagy 
competent tumor cells, in vivo. (A) FVBN202 mice (n = 7) were challenged i.v. with 106 cells ADR-treated dormant control 
MMC (MMC), or ADR-treated dormant ATG5KD MMC (ATG5KD MMC). Animals were euthanized as soon as they became moribund. 
Representative tumor relapse in the lung and survival curve are shown. (B) Relapsed tumors were collected and immunohistochemistry 
slides were prepared by either staining samples with hematoxylin and eosin (H&E) or by Ki67 staining followed by subsequent digitization 
and analysis with NDP View software (Hamamatsu Photonics). At twenty-times magnification, three representative 0.02 mm2 areas were 
chosen from the H&E slides containing approximately 100 cells to measure nuclear envelope size. Cells containing a nuclear envelope 
equal to or greater than 16 um with visible multi-nuclei were considered polyploid-like or high grade cells. The corresponding cell was then 
analyzed on the Ki67 stained slide to determine Ki67 expression levels. Data was collected from three biological samples. Significance is 
based on a two-tailed t-test of p < 0.05.
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include: anti-CD16/32 (clone 93), APC-anti-mouse IgG 
(Poly4053), PE-Ki67 (16A8), Alexa flour 488-Ki67 
(11F6), Brilliant Violet 605-CD45 (30-F11), FITC-
Annexin V, APC-Annexin V, 7-AAD viability staining 
solution and Propidium Iodide solution (PI), mouse 
anti-rat neu (anti–c-Erb2/c-Neu; 7.16.4, Calbiochem, 
Billerica, MA), FITC-FVS (BD Biosciences). All 
reagents were used at the manufacturer’s recommended 
concentration. 
Mice
FVBN202 transgenic female mice (The Jackson 
Laboratory; Bar Harbor, ME) were used. These mice 
overexpress non-mutated, non-activated rat neu transgene 
under the regulation of the mouse mammary tumor 
virus promoter  [28]. These mice develop premalignant 
mammary hyperplasia similar to ductal carcinoma in situ 
prior to the development of spontaneous carcinoma  [29]. 
These studies have been reviewed and approved by the 
Institutional Animal Care and Use Committee at Virginia 
Commonwealth University. 
Experimental tumor dormancy 
In vitro tumor dormancy was established by the 
treatment of MMC or ATG5KD MMC tumor cells with 3 daily 
doses of ADR (Sigma-Aldrich, 1uM for 2 hrs). During ADR 
treatment, MMC tumor cells were cultured without or with 
CQ (Sigma-Aldrich, 10 uM, 3 hrs prior to and during ADR 
treatment). By 2 weeks after the treatment, all groups did not 
show any increases in the number of adherent cells, which is 
the characteristic of tumor dormancy. For in vivo induction 
of tumor dormancy, FVBN202 mice were challenged with 
ADR-treated dormant MMC or ATG5KD MMC (i.v. injection 
of 1 million viable cells), or untreated MMC followed by 3 
weekly treatments of ADR (i.v., 9 mg/kg) or with 3 weekly 
treatment of ADR + 60 mg/kg CQ (i.p.). 
Cytotoxicity assay
Freshly isolated tumor-primed splenic T 
cells or ex vivo expanded splenic T cells were 
cultured with MMC at a 10:1 E:T ratio in 3 ml 
complete medium (RPMI-1640 supplemented with 
100 U/ml of penicillin, 100 µg/ml streptomycin, 
10% FBS, 10 mM L-glutamine and 5 × 10–5 
M 2-mercaptoethanol) with 20U/ml of IL-2 (Peprotech) 
in 6 well culture dishes. After 48 hs cells were 
harvested and stained for neu (anti-c-Erb2/c–Neu, 
Calbiochem), Annexin V and PI according to the 
manufacturer’s protocol (BD Pharmingen). Flow 
cytometry was used to analyze the viability of neu 
positive cells  [17, 30].
IFN-γ ELISA. Reprogrammed immune cells were 
cultured in complete medium with irradiated (140 Gy) 
tumor cells, ADR-treated dormant MMC or ADR+CQ-
treated dormant MMC at a 10:1 ratio for 20 hrs. 
Supernatants were then collected and stored at −80°C until 
assayed. IFN-γ was detected using a Mouse IFN-γ ELISA 
kit (BD Biosciences), according to the manufacturer’s 
protocol  [30]. 
Statistical analysis
Data are summarized as means and standard errors 
of the mean (SEM) with differences between groups 
being illustrated with graphical data presented as mean 
± SEM. Statistical comparisons were made using a one-
tailed or two-tailed Student t test and a p-value < 0.05 was 
considered significant (*: < 0.05, **: < 0.005. ***: < 0.0005, 
****: < 0.00005).
Figure 7: Autophagy knockdown tumor cells become resistant to T cell-induced apoptosis. Neu overexpressing autophagy-
deficient MMC (ATG5KD MMC) or autophagy-competent MMC (MMC) were co-cultured with MMC-sensitized T cells and then gated 
CD45-Neu+ tumor cells were analyzed by Annexin V/PI staining. Data represents triplicate experiments.
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